Generalised Anxiety Disorder Clinical Trial
Official title:
Smartphone-Delivered Lifestyle Medicine Intervention for Generalized Anxiety Symptoms: A Randomized Controlled Trial
This study will examine the effects of smartphone-based lifestyle medicine for alleviating generalised anxiety symptoms in Chinese population. Since a range of lifestyle factors are involved in the pathogenesis and progression of generalised anxiety disorder ( Cox & Olatunji, 2016; Dale et al., 2014; Vøllestad et al., 2012), modifying different lifestyle factors simultaneously, for examples, diet, exercise, stress and sleep, may be effective to reduce generalised anxiety symptoms. Recent studies indicate that service users are showing an increasing interest in self-help interventions for common mental disorders because of their accessibility and low cost (Marshall et al., 2021; Weisel et al., 2019). Nonetheless, to date, only limited self-help interventions that target lifestyle medicine for generalised anxiety symptoms are available. This study will be a randomised controlled trial on the effects of a self-help smartphone-based lifestyle medicine intervention for reducing generalised anxiety symptoms in Chinese population. Prior to all study procedures, eligible participants will be required to complete an online informed consent (with telephone support). Around 50 eligible participants will be randomly assigned to either smartphone-based lifestyle medicine (LM group) or the waitlist control group (WL group) in a ratio of 1:1. The randomization will be performed by an independent assessor using a computer-generated list of numbers. Participants in the LM group will receive the multicomponent lifestyle medicine intervention via the app for 8 weeks, whilst the WL control group will receive the intervention after trial completion. The primary outcomes will be the level of generalised anxiety symptoms at immediate and 3-month post-intervention assessments; while the secondary outcomes will be the level of depressive symptoms, insomnia symptoms, physical activity, health-related quality of life, functional impairment, health-promoting behaviours, and intervention acceptability at immediate and 3-month post-intervention assessments.
| Status | Not yet recruiting |
| Enrollment | 50 |
| Est. completion date | September 2023 |
| Est. primary completion date | December 2022 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Hong Kong residents - Aged = 18 years - Have a Generalized Anxiety Disorder-7 (GAD-7) score = 8 - Able to read Chinese and type in Chinese or English - Have an Internet-enabled mobile device (iOS or Android operating system) - Willing to provide informed consent and comply with the trial protocol Exclusion Criteria: - Current involvement in psychotherapy or recent changes in medication for anxiety - A Patient Health Questionnaire-9 (PHQ-9) item 9 score > 2, indicating a serious level of suicidal risk (referral information to professional mental health services will be provided) - Self-disclosure of having unsafe health conditions for which physical activity or a change in diet was contraindicated by physicians - Self-disclosure of a diagnosis of any major psychiatric, medical or neurocognitive disorders that make participation unsuitable or that may interfere with the adherence to the lifestyle modifications |
| Country | Name | City | State |
|---|---|---|---|
| Hong Kong | The Chinese University of Hong Kong | Sha Tin |
| Lead Sponsor | Collaborator |
|---|---|
| Chinese University of Hong Kong |
Hong Kong,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in the Generalized Anxiety Disorder-7 (GAD-7) | GAD-7 is a seven-item scale for assessing the level of generalized anxiety in the past two weeks. It comprises questions related to feelings of anxious and worry in daily lives. This four-point Likert scale is rated from 0 (not at all) to 3 (almost everyday), and the cut off score on the sum of each item will be the standard to differentiate the anxiety level (5, 10, 15 correspond to mild, moderate and severe respectively) | Baseline, immediate post-intervention, and 3-month post-intervention | |
| Secondary | Change in the Patient Health Questionnaire (PHQ-9) | PHQ-9 is a nine-item scale for assessing the level of depressive symptoms in the past two weeks. This four-point Likert scale is rated from 0 (not at all) to 3 (almost every day), and the cut off scores on the sum of each item will be the standard to differentiate the depressive level (5, 10, 15, 20 correspond to mild, moderate, moderately severe and severe respectively) | Baseline, immediate post-intervention, and 3-month post-intervention | |
| Secondary | Change in the Insomnia Severity Index (ISI) | ISI is a seven-item scale for measuring the severity of sleep disturbance. This five-point Likert scale is rated from 0 to 4 for each item, and a higher total score indicates the more severe of the insomnia condition (8, 15, 22 correspond to subthreshold insomnia, moderate clinical insomnia and severe clinical insomnia respectively). | Baseline, immediate post-intervention, and 3-month post-intervention | |
| Secondary | Change in the Short Form (Six-Dimension) Health Survey (SF-6D) | SF-6D is a single index and preference-based questionnaire for measuring individual's quality of lives in the following six domains, including physical functioning, role limitation, social functioning, bodily pain, mental health, and vitality. | Baseline, immediate post-intervention, and 3-month post-intervention | |
| Secondary | Change in the Health-Promoting Lifestyle Profile (HPLP II) | HPLP-II is a 52-item questionnaire for measuring the present lifestyle or personal habits with six sub-scale domains, including health responsibility, physical activity, nutrition, spiritual growth, interpersonal relations, and stress management. The inventory uses a four-point Likert scale, from 1 (never) to 4 (routinely), to evaluate the frequency of items asked to the participants. | Baseline, immediate post-intervention, and 3-month post-intervention | |
| Secondary | Change in the Sheehan Disability Scale (SDS) | SDS is a three-item, self-reported 10-point visual analog scale on measuring one's severity level of impairment on three dimensions, including work/school, social life, and family life. | Baseline, immediate post-intervention, and 3-month post-intervention | |
| Secondary | Change in the Credibility-Expectancy Questionnaire (CEQ) | CEQ is a self-reported 6-item inventory for assessing one's attitude towards the credibility and expectancy of the intervention contents. | Baseline and immediate post-intervention | |
| Secondary | Change in the Treatment Acceptance Questionnaire (TAQ) | TAQ is a self-reported, six-item questionnaire that is rated by a seven-point Likert scale from 1 to 7, and it aims at evaluating the clients' attitude toward the treatment sessions by six domains, including acceptability, ethics, effectiveness, negative side effects, the therapist's knowledge, and the therapist's trustworthiness. | Baseline and immediate post-intervention | |
| Secondary | Change in the International Physical Activities Questionnaire-Chinese version (IPAQ-C) | IPAQ-C is a 5-item questionnaire that measures the amount of sitting time, walking time, and moderate and vigorous exercise during the last 7 days. Different exercise types are categorized and rated as different metabolic equivalent tasks, while a higher score of the sum of total items represents a higher intense of activity level. | Baseline, immediate post-intervention, and 3-month post-intervention |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03131505 -
INCLUDE: Using Lived Experience to Improve Mental Health Diagnosis v1
|
||
| Recruiting |
NCT05549102 -
CBT and the Neural Circuits of Anxiety
|
||
| Recruiting |
NCT03813290 -
A Neuro-Technological Intervention for Adolescents With GAD
|
N/A | |
| Terminated |
NCT02347033 -
Trial of Sertraline Versus Cognitive Behaviour Therapy for Generalised Anxiety
|
Phase 4 |